Several other global leaders of the G10K and B10K consortia will also contribute use of their recently acquired PacBio® Sequel Systems toward their goal of creating de novo assembled vertebrate genomes, including
The G10K project was established in 2009 by a consortium of biologists and genome scientists, including
In the first phase of the projects, the two groups collaborated. One outcome was the
At that time, the consortia were using short-read technologies, but have since discovered that they will be able to make even further scientific advances with longer-read technology. Thus, the G10K and the B10K initiatives
will include the Sequel Systems for the next phases of these projects. They intend to sequence the genomes for several thousand vertebrate species with PacBio technology for diploid-resolved, high-quality de novo genome assemblies, and perform subsequent chromosome-level scaffolding with complementary approaches, including BioNano Genomics’ optical genome mapping, Dovetail’s proximity in vitro genome mapping, and Phase Genomics Hi-C mapping.
PacBio sequencing technology will allow
About Pacific Biosciences
technology, Pacific Biosciences’ products enable: de novo genome assembly to finish genomes in order to more fully identify, annotate and decipher genomic structures; full-length transcript analysis to improve annotations in reference genomes, characterize alternatively spliced isoforms in important gene families, and find novel genes; targeted sequencing to more comprehensively characterize genetic variations; and real-time kinetic information for epigenome characterization. Pacific Biosciences’ technology provides high accuracy, ultra-long reads, uniform coverage, and is the only DNA sequencing technology that provides the ability to simultaneously detect epigenetic changes. PacBio® sequencing systems, including consumables and software, provide a simple, fast, end-to-end workflow for SMRT Sequencing. More information is available at www.pacb.com.
All statements in this press release that are not historical are forward-looking statements, including, among other things, statements relating to product orders, future uses, quality or performance of, or benefits of using, products or technologies, expected benefits from the G10K and the B10K initiatives, and other future events. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, changes in circumstances and other factors that are, in some cases, beyond Pacific Biosciences’ control and could cause actual results to differ materially from the information expressed or implied by forward-looking statements made in this press release. Factors that could materially affect actual results can be found in Pacific Biosciences’ most recent filings with the Securities and Exchange Commission, including Pacific Biosciences’ most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption “Risk Factors.”
Pacific Biosciences undertakes no obligation to revise or update information in this press release to reflect events or circumstances in the future, even if new information becomes available.
Associated twitter handles and hashtags
News Provided by Acquire Media